SCHEMBL4858516

SCHEMBL4858516

COc1cc(C2=NNC(=O)/C2=C/N(C)C)cc(OC)c1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
LMNA P02545 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 5/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
GLA P06280 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TUBB4A P04350 3/20 0.39
TUBB P07437 3/20 0.39
TUBA3C P0DPH7 3/20 0.39
TUBA1B P68363 3/20 0.39
TUBA4A P68366 3/20 0.39
TUBB4B P68371 3/20 0.39
TUBB3 Q13509 3/20 0.39
TUBB2A Q13885 3/20 0.39
TUBB8 Q3ZCM7 3/20 0.39
TUBA3E Q6PEY2 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4858521 1.00 ALDH1A1 (0.58) ALDH1A1LMNAL3MBTL1KDM4EMEN1
SCHEMBL14003588 1.00 ALDH1A1 (0.58) ALDH1A1LMNAL3MBTL1KDM4EMEN1
SCHEMBL4861456 0.85 LMNA (0.60) ALDH1A1LMNAL3MBTL1KDM4EMAPT
SCHEMBL4861458 0.85 LMNA (0.60) ALDH1A1LMNAL3MBTL1KDM4EMAPT
SCHEMBL4865450 0.75 ALDH1A1 (0.42) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL4865457 0.75 ALDH1A1 (0.42) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL4859346 0.73 ALDH1A1 (0.41) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL4859336 0.73 ALDH1A1 (0.41) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL4859407 0.69 ALDH1A1 (0.45) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL4859398 0.69 ALDH1A1 (0.45) ALDH1A1LMNAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-06 US disclosed
US-6916798-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-07-12 US disclosed
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US disclosed
WO-2003011287-A1 PYRAZOLON DERIVATIVES AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A ALDH1A1 3536/4885LMNA 828/4885L3MBTL1 4335/4885
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A ALDH1A1 3536/4885LMNA 828/4885L3MBTL1 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.